SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic...

Quality control is a crucial but inefficient process in most manufacturing applications. Medicine producers face even more challenges than most. Their quality standards are...

ESET products and research have been protecting Ukrainian IT infrastructure for years. Since the start of the war in February 2022, we have prevented...

By Kenna Hughes-Castleberry posted 17 Feb 2024 Quantum News Briefs: February 16, 2024:  Delft University of Technology Researchers Propose...

Directors join board after agreement with Icahn Enterprises NEW YORK–(BUSINESS WIRE)–JetBlue (NASDAQ: JBLU) today announced that it has entered into an agreement with Icahn Enterprises...

POTOMAC, Md.–(BUSINESS WIRE)–#AD–IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024...

This post is co-written with Ilan Geller, Shuyu Yang and Richa Gupta from Accenture. Bringing innovative new pharmaceuticals drugs to market is a long...

– The Company is targeting a Phase 1 trial in 2024 – POTOMAC, Md.–(BUSINESS WIRE)–#AD–IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:...

PARIS–(BUSINESS WIRE)–AQEMIA continues to grow rapidly in its effort to discover new drugs with their generative-AI fueled by deep physics. After raising €30M last...

TOKYO, Feb 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd...

Aggregating channels with precision outreach to patients, family members, and oncologists/hematologists improves clinical research access for all MALMO, Sweden & NEW YORK–(BUSINESS WIRE)–Trialbee, your global...